Skip to main content

Advertisement

SpringerLink
Log in

Cutaneous Drug Reactions in the Elderly

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Cutaneous adverse drug reactions comprise a significant proportion of all adverse drug reactions. They may mimic other dermatologic or systemic illnesses and may cause significant morbidity or mortality. Seven morphologic groups encompass the most commonly encountered cutaneous drug reaction syndromes: exanthematous (maculopapular), dermatitic/eczematous, urticarial, pustular, blistering, purpuric, and erythrodermic. Drug reactions may have significant downstream consequences for the older individual.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12. doi:10.1056/NEJMsa1103053.

    Article  CAS  PubMed  Google Scholar 

  2. Passarelli MCG, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging. 2005;22:767–77.

    Article  PubMed  Google Scholar 

  3. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107–16.

    Article  PubMed  Google Scholar 

  4. Koelblinger P, Dabade TS, Gustafson CJ, et al. Skin manifestations of outpatient adverse drug events in the United States: a national analysis. J Cutan Med Surg. 2013;17:269–75. doi:10.2310/7750.2013.12096.

    Article  PubMed  Google Scholar 

  5. Yalcin B, Tamer E, Toy GG, et al. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. Int J Dermatol. 2006;45:672–6. doi:10.1111/j.1365-4632.2005.02607.x.

    Article  PubMed  Google Scholar 

  6. Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, et al. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry. 2009;70:1258–65. doi:10.4088/JCP.08m04563.

    Article  PubMed  Google Scholar 

  7. del Campos-Fernandez MM, de Leon-Rosales SP, Archer-Dubon C, Orozco-Topete R. Incidence and risk factors for cutaneous adverse drug reactions in an intensive care unit. Rev Invest Clin. 2005;57:770–4.

    Google Scholar 

  8. Bastuji-Garin S, Zahedi M, Guillaume JC, Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing. 1993;22:450–6.

    Article  CAS  PubMed  Google Scholar 

  9. Bigby M, Jick S, Jick H, Arndt K. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 198. JAMA. 1975;1986(256):3358–63.

    Google Scholar 

  10. van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol. 1998;51:703–8.

    Article  PubMed  Google Scholar 

  11. Stern RS. Utilization of hospital and outpatient care for adverse cutaneous reactions to medications. Pharmacoepidemiol Drug Saf. 2005;14:677–84. doi:10.1002/pds.1065.

    Article  PubMed  Google Scholar 

  12. Hernandez-Salazar A, de Leon-Rosales SP, Rangel-Frausto S, et al. Epidemiology of adverse cutaneous drug reactions: a prospective study in hospitalized patients. Arch Med Res. 2006;37:899–902. doi:10.1016/j.arcmed.2006.03.010.

    Article  PubMed  Google Scholar 

  13. Park CS, Kim T-B, Kim SL, et al. The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea. Pharmacoepidemiol Drug Saf. 2008;17:919–25. doi:10.1002/pds.1612.

    Article  PubMed  Google Scholar 

  14. Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. 2003;149:1018–22.

    Article  CAS  PubMed  Google Scholar 

  15. Calderón-Larrañaga A, Poblador-Plou B, González-Rubio F, et al. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? Br J Gen Pract. 2012;62:e821–6. doi:10.3399/bjgp12X659295.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74. doi:10.1186/s12916-015-0322-7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62:722–7.

    Article  PubMed  Google Scholar 

  18. Woo J, Leung J. Multi-morbidity, dependency, and frailty singly or in combination have different impact on health outcomes. Age Dordr Neth. 2014;36:923–31. doi:10.1007/s11357-013-9590-3.

    Article  Google Scholar 

  19. Aarts S, Patel KV, Garcia ME, et al. Co-Presence of multimorbidity and disability with frailty: an examination of heterogeneity in the frail older population. J Frailty Aging. 2015;4:131–8. doi:10.14283/jfa.2015.45.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Rolland Y, Morley JE. Frailty and polypharmacy. J Nutr Health Aging. 2016;20:645–6. doi:10.1007/s12603-015-0510-3.

    Article  CAS  PubMed  Google Scholar 

  21. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.

    Article  CAS  PubMed  Google Scholar 

  22. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95. doi:10.1503/cmaj.050051.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Crome P, Lally F. Frailty: joining the giants. CMAJ. 2011;183:889–90. doi:10.1503/cmaj.110626.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2012;381:752–62. doi:10.1016/S0140-6736(12)62167-9.

    Article  Google Scholar 

  25. Oresanya LB, Lyons WL, Finlayson E. Preoperative assessment of the older patient: a narrative review. JAMA. 2014;311:2110–20. doi:10.1001/jama.2014.4573.

    Article  CAS  PubMed  Google Scholar 

  26. Sullivan JR, Shear NH. Drug eruptions and other adverse drug effects in aged skin. Clin Geriatr Med. 2002;18:21–42. doi:10.1016/S0749-0690(03)00032-6.

    Article  PubMed  Google Scholar 

  27. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–8. doi:10.1038/clpt.2009.252.

    Article  CAS  PubMed  Google Scholar 

  28. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–80. doi:10.1111/bjd.12501.

    Article  CAS  PubMed  Google Scholar 

  29. Lin Y-F, Yang C-H, Sindy H, et al. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis. 2014;58:1377–85. doi:10.1093/cid/ciu126.

    Article  CAS  PubMed  Google Scholar 

  30. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7. doi:10.1056/NEJM199512143332404.

    Article  CAS  PubMed  Google Scholar 

  31. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35–44. doi:10.1038/sj.jid.5701033.

    Article  CAS  PubMed  Google Scholar 

  32. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP): results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157:989–96. doi:10.1111/j.1365-2133.2007.08156.x.

    Article  CAS  PubMed  Google Scholar 

  33. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139:683–93.

    Article  CAS  PubMed  Google Scholar 

  34. Tuchinda P, Chularojanamontri L, Sukakul T, et al. Cutaneous adverse drug reactions in the elderly: a retrospective analysis in Thailand. Drugs Aging. 2014;31:815–24. doi:10.1007/s40266-014-0209-x.

    Article  CAS  PubMed  Google Scholar 

  35. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670–4. doi:10.1056/NEJM199306103282304.

    Article  CAS  PubMed  Google Scholar 

  36. Stern RS. Exanthematous drug eruptions. N Engl J Med. 2012;366:2492–501. doi:10.1056/NEJMcp1104080.

    Article  CAS  PubMed  Google Scholar 

  37. Jick H, Porter JB. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia. J Clin Pharmacol. 1981;21:456–8.

    Article  CAS  PubMed  Google Scholar 

  38. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;25(15):31. doi:10.1186/s12877-015-0029-9.

    Article  Google Scholar 

  39. McDonald K, Trick L, Boyle J. Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol Clin Exp. 2008;23:555–70. doi:10.1002/hup.962.

    Article  Google Scholar 

  40. Beauregard S, Gilchrest BA. A survey of skin problems and skin care regimens in the elderly. Arch Dermatol. 1987;123:1638–43.

    Article  CAS  PubMed  Google Scholar 

  41. Fenske NA, Lober CW. Structural and functional changes of normal aging skin. J Am Acad Dermatol. 1986;15:571–85. doi:10.1016/S0190-9622(86)70208-9.

    Article  CAS  PubMed  Google Scholar 

  42. Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol. 2009;10:73–86.

    Article  PubMed  Google Scholar 

  43. Proksch E. Antilipemic drug-induced skin manifestations. Hautarzt Z Für Dermatol Venerol Verwandte Geb. 1995;46:76–80.

    Article  CAS  Google Scholar 

  44. Hatwal A, Bhatt RP, Agrawal JK, et al. Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol. 1988;68:84–7.

    CAS  PubMed  Google Scholar 

  45. Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. 2011;40:23–9. doi:10.1093/ageing/afq140.

    Article  PubMed  Google Scholar 

  46. Mangelsdorf HC, Fleischer AB, Sherertz EF. Patch testing in an aged population without dermatitis: high prevalence of patch test positivity. Am J Contact Dermat. 1996;7:155–7.

    CAS  PubMed  Google Scholar 

  47. Goh CL, Ling R. A retrospective epidemiology study of contact eczema among the elderly attending a tertiary dermatology referral centre in Singapore. Singap Med J. 1998;39:442–6.

    CAS  Google Scholar 

  48. Walton S, Nayagam AT, Keczkes K. Age and sex incidence of allergic contact dermatitis. Contact Dermat. 1986;15:136–9.

    Article  CAS  Google Scholar 

  49. Tavadia S, Bianchi J, Dawe RS, et al. Allergic contact dermatitis in venous leg ulcer patients. Contact Dermat. 2003;48:261–5.

    Article  CAS  Google Scholar 

  50. Gooptu C, Powell SM. The problems of rubber hypersensitivity (types I and IV) in chronic leg ulcer and stasis eczema patients. Contact Dermatitis. 1999;41:89–93.

    Article  CAS  PubMed  Google Scholar 

  51. Isaksson M, Bruze M, Björkner B, et al. The benefit of patch testing with a corticosteroid at a low concentration. Am J Contact Dermat. 1999;10:31–3.

    Article  CAS  PubMed  Google Scholar 

  52. Winblad B, Grossberg G, Frölich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69:S14–22. doi:10.1212/01.wnl.0000281847.17519.e0.

    Article  CAS  PubMed  Google Scholar 

  53. Greenspoon J, Herrmann N, Adam DN. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. CNS Drugs. 2011;25:575–83. doi:10.2165/11592230-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  54. González E, González S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol. 1996;35:871–85 (quiz 886–7).

    Article  PubMed  Google Scholar 

  55. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf. 2002;25:345–72.

    Article  CAS  PubMed  Google Scholar 

  56. Epstein JH. Phototoxicity and photoallergy. Semin Cutan Med Surg. 1999;18:274–84.

    Article  CAS  PubMed  Google Scholar 

  57. Kaidbey KH, Messenger JL. The clinical spectrum of the persistent light reactor. Arch Dermatol. 1984;120:1441–8.

    Article  CAS  PubMed  Google Scholar 

  58. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics. Toronto, ON: Canadian Cancer Society; 2016.

  59. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14:212–6.

    Article  CAS  PubMed  Google Scholar 

  60. Robert C, Soria J-C, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6:491–500. doi:10.1016/S1470-2045(05)70243-6.

    Article  CAS  PubMed  Google Scholar 

  61. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161:1045–51. doi:10.1111/j.1365-2133.2009.09290.x.

    Article  CAS  PubMed  Google Scholar 

  62. Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol Tor Ont. 2009;16:16–26.

    CAS  Google Scholar 

  63. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91. doi:10.1093/annonc/mdv383.

    CAS  PubMed  Google Scholar 

  64. Luu M, Lai SE, Patel J, et al. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed. 2007;23:42–5. doi:10.1111/j.1600-0781.2007.00273.x.

    Article  PubMed  Google Scholar 

  65. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24:1691–7. doi:10.1093/annonc/mdt015.

    Article  CAS  PubMed  Google Scholar 

  66. Gelot P, Dutartre H, Khammari A, et al. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol. 2013;22:297–8. doi:10.1111/exd.12119.

    Article  CAS  PubMed  Google Scholar 

  67. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65. doi:10.1056/NEJMoa0809493.

    Article  CAS  PubMed  Google Scholar 

  68. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999–2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134(1318–28):e7. doi:10.1016/j.jaci.2014.08.018.

    Google Scholar 

  69. Harduar-Morano L, Simon MR, Watkins S, Blackmore C. Algorithm for the diagnosis of anaphylaxis and its validation using population-based data on emergency department visits for anaphylaxis in Florida. J Allergy Clin Immunol. 2010;126(98–104):e4. doi:10.1016/j.jaci.2010.04.017.

    Google Scholar 

  70. Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:1075–83. doi:10.1016/j.jaci.2013.10.029.

    Article  PubMed  Google Scholar 

  71. Lieberman P, Simons FER. Anaphylaxis and cardiovascular disease: therapeutic dilemmas. Clin Exp Allergy. 2015;45:1288–95. doi:10.1111/cea.12520.

    Article  CAS  PubMed  Google Scholar 

  72. Kawano T, Scheuermeyer FX, Stenstrom R, et al. Epinephrine use in older patients with anaphylaxis: clinical outcomes and cardiovascular complications. Resuscitation. 2017;112:53–8. doi:10.1016/j.resuscitation.2016.12.020.

    Article  PubMed  Google Scholar 

  73. Campbell RL, Bellolio MF, Knutson BD, et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol Pract. 2015;3:76–80. doi:10.1016/j.jaip.2014.06.007.

    Article  PubMed  Google Scholar 

  74. Simon RA, Namazy J. Adverse reactions to aspirin and nonsteroidal antiinflammatory drugs (NSAIDs). Clin Rev Allergy Immunol. 2003;24:239–52. doi:10.1385/CRIAI:24:3:239.

    Article  CAS  PubMed  Google Scholar 

  75. Piller LB, Ford CE, Davis BR, et al. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2006;8:649–56 (quiz 657–8).

    Article  Google Scholar 

  76. Venzor J, Lee WL, Huston DP. Urticarial vasculitis. Clin Rev Allergy Immunol. 2002;23:201–16. doi:10.1385/CRIAI:23:2:201.

    Article  PubMed  Google Scholar 

  77. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124:588–97. doi:10.1016/j.amjmed.2011.01.017.

    Article  CAS  PubMed  Google Scholar 

  78. Chen Y-C, Chang C-Y, Cho Y-T, et al. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68:459–65. doi:10.1016/j.jaad.2012.08.009.

    Article  PubMed  Google Scholar 

  79. Botella-Estrada R, Sanmartín O, Oliver V, et al. Erythroderma: a clinicopathological study of 56 cases. Arch Dermatol. 1994;130:1503–7.

    Article  CAS  PubMed  Google Scholar 

  80. Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol. 2005;5:5. doi:10.1186/1471-5945-5-5.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Yuan X-Y, Guo J-Y, Dang Y-P, et al. Erythroderma: a clinical-etiological study of 82 cases. Eur J Dermatol. 2010;20:373–7. doi:10.1684/ejd.2010.0943.

    PubMed  Google Scholar 

  82. Sigurdsson V, Toonstra J, Hezemans-Boer M, van Vloten WA. Erythroderma: a clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol. 1996;35:53–7.

    Article  CAS  PubMed  Google Scholar 

  83. Pal S, Haroon TS. Erythroderma: a clinico-etiologic study of 90 cases. Int J Dermatol. 1998;37:104–7.

    Article  CAS  PubMed  Google Scholar 

  84. Hasan T, Jansén CT. Erythroderma: a follow-up of fifty cases. J Am Acad Dermatol. 1983;8:836–40.

    Article  CAS  PubMed  Google Scholar 

  85. Loukas E. High-output heart failure in a patient with exfoliative erythrodermic psoriasis. J Hosp Med. 2010;5:162–3.

    Google Scholar 

  86. Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the “red man”. Clin Dermatol. 2005;23:206–17. doi:10.1016/j.clindermatol.2004.06.018.

    Article  PubMed  Google Scholar 

  87. Lin T-K, Hsu MM-L, Lee JY-Y. Clinical resemblance of widespread bullous fixed drug eruption to Stevens–Johnson syndrome or toxic epidermal necrolysis: report of two cases. J Formos Med Assoc Taiwan Yi Zhi. 2002;101:572–6.

    PubMed  Google Scholar 

  88. Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9:316–21. doi:10.1097/ACI.0b013e32832cda4c.

    Article  PubMed  Google Scholar 

  89. Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013;168:726–32. doi:10.1111/bjd.12133.

    Article  CAS  PubMed  Google Scholar 

  90. Brenner S, Wolf R, Ruocco V. Contact pemphigus: a subgroup of induced pemphigus. Int J Dermatol. 1994;33:843–5. doi:10.1111/j.1365-4362.1994.tb01016.x.

    Article  CAS  PubMed  Google Scholar 

  91. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29:455–7. doi:10.1016/j.clindermatol.2011.01.016.

    Article  PubMed  Google Scholar 

  92. Korman NJ, Eyre RW, Zone J, Stanley JR. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol. 1991;96:273–6.

    Article  CAS  PubMed  Google Scholar 

  93. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris–incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180. doi:10.1136/bmj.a180.

    Article  CAS  PubMed  Google Scholar 

  94. Huang Y-H, Kuo C-F, Chen Y-H, Yang Y-W. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study. J Invest Dermatol. 2012;132:92–7. doi:10.1038/jid.2011.249.

    Article  CAS  PubMed  Google Scholar 

  95. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol. 1982;7:221–8.

    Article  CAS  PubMed  Google Scholar 

  96. Hsu DY, Brieva J, Sinha AA, et al. Comorbidities and inpatient mortality for pemphigus in the U.S.A. Br J Dermatol. 2016;174:1290–8. doi:10.1111/bjd.14463.

    Article  CAS  PubMed  Google Scholar 

  97. Baican A, Chiorean R, Leucuta DC, et al. Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study. Orphanet J Rare Dis. 2015;10:48. doi:10.1186/s13023-015-0263-4.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Lee JJ, Downham TF. Furosemide-induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol. 2006;5:562–4.

    PubMed  Google Scholar 

  99. Patsatsi A, Vyzantiadis T-A, Chrysomallis F, et al. Medication history of a series of patients with bullous pemphigoid from northern Greece: observations and discussion. Int J Dermatol. 2009;48:132–5. doi:10.1111/j.1365-4632.2009.03839.x.

    Article  PubMed  Google Scholar 

  100. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28:1133–40. doi:10.1111/jdv.12366.

    Article  CAS  PubMed  Google Scholar 

  101. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid: a case-control study. Arch Dermatol. 1996;132:272–6.

    Article  CAS  PubMed  Google Scholar 

  102. Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011;131:637–43. doi:10.1038/jid.2010.301.

    Article  CAS  PubMed  Google Scholar 

  103. Lloyd-Lavery A, Chi C-C, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013;149:58–62. doi:10.1001/2013.jamadermatol.376.

    Article  PubMed  Google Scholar 

  104. Pasmatzi E, Monastirli A, Habeos J, et al. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care. 2011;34:e133. doi:10.2337/dc11-0804.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Skandalis K, Spirova M, Gaitanis G, et al. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26:249–53. doi:10.1111/j.1468-3083.2011.04062.x.

    Article  CAS  PubMed  Google Scholar 

  106. Aouidad I, Fite C, Marinho E, et al. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol. 2013;149:243–5. doi:10.1001/jamadermatol.2013.1073.

    Article  PubMed  Google Scholar 

  107. Roujeau J-C, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134:465. doi:10.1001/archderm.134.4.465.

    Article  CAS  PubMed  Google Scholar 

  108. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138:903–8.

    Article  PubMed  Google Scholar 

  109. Joly P, Fontaine J, Roujeau J-C. The role of topical corticosteroids in bullous pemphigoid in the elderly. Drugs Aging. 2005;22:571–6.

    Article  CAS  PubMed  Google Scholar 

  110. Joly P, Roujeau J-C, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321–7. doi:10.1056/NEJMoa011592.

    Article  CAS  PubMed  Google Scholar 

  111. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143:1536–42. doi:10.1001/archderm.143.12.1536.

    Article  CAS  PubMed  Google Scholar 

  112. Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP. A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: a real and separate nosological entity? J Am Acad Dermatol. 2012;66:988–94. doi:10.1016/j.jaad.2011.09.018.

    Article  PubMed  Google Scholar 

  113. Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol. 2012;30:38–50. doi:10.1016/j.clindermatol.2011.03.008.

    Article  PubMed  Google Scholar 

  114. Chanal J, Ingen-Housz-Oro S, Ortonne N, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol. 2013;169:1041–8. doi:10.1111/bjd.12488.

    Article  CAS  PubMed  Google Scholar 

  115. Mittmann N, Chan BC, Knowles S, Shear NH. IVIG for the treatment of toxic epidermal necrolysis. Skin Ther Lett. 2007;12:7–9.

    CAS  Google Scholar 

  116. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53. doi:10.1046/j.1523-1747.2000.00061.x.

    Article  CAS  PubMed  Google Scholar 

  117. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133:1197–204. doi:10.1038/jid.2012.510.

    Article  CAS  PubMed  Google Scholar 

  118. Chantaphakul H, Sanon T, Klaewsongkram J. Clinical characteristics and treatment outcome of Stevens–Johnson syndrome and toxic epidermal necrolysis. Exp Ther Med. 2015;10(2):519–24. doi:10.3892/etm.2015.2549.

    Article  PubMed  PubMed Central  Google Scholar 

  119. McGill V, Kowal-Vern A, Gamelli RL. Outcome for older burn patients. Arch Surg. 2000;135:320–5. doi:10.1001/archsurg.135.3.320.

    Article  CAS  PubMed  Google Scholar 

  120. Mahar P, Wasiak J, Bailey M, Cleland H. Clinical factors affecting mortality in elderly burn patients admitted to a burns service. Burns. 2008;34:629–36. doi:10.1016/j.burns.2007.09.006.

    Article  PubMed  Google Scholar 

  121. Lundgren RS, Kramer CB, Rivara FP, et al. Influence of comorbidities and age on outcome following burn injury in older adults. J Burn Care Res. 2009;30:307–14. doi:10.1097/BCR.0b013e318198a416.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Von Wild T, Stollwerck PL, Namdar T, et al. Are multimorbidities underestimated in scoring systems of Stevens–Johnson syndrome and toxic epidermal necrolysis like in SCORTEN? EPlasty. 2012;12:e35.

  123. Mittmann N, Chan B, Knowles S, et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol. 2006;7:359–68.

    Article  PubMed  Google Scholar 

  124. Chen J, Wang B, Zeng Y, Xu H. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases. Eur J Dermatol. 2010;20:743–7. doi:10.1684/ejd.2010.1077.

    CAS  PubMed  Google Scholar 

  125. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015;54:108–15. doi:10.1111/ijd.12423.

    Article  PubMed  Google Scholar 

  126. Gubinelli E, Canzona F, Tonanzi T, et al. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009;36:150–3. doi:10.1111/j.1346-8138.2009.00616.x.

    Article  PubMed  Google Scholar 

  127. Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71:278–83. doi:10.1016/j.jaad.2014.04.044.

    Article  CAS  PubMed  Google Scholar 

  128. Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28:113–9.

    Article  CAS  PubMed  Google Scholar 

  129. Chang S-L, Huang Y-H, Yang C-H, et al. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol. 2008;88:363–5. doi:10.2340/00015555-0438.

    PubMed  Google Scholar 

  130. Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:1–8. doi:10.1155/2015/260928.

    Article  Google Scholar 

  131. Peermohamed S, Haber RM. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: a case report and review of the literature. Arch Dermatol. 2011;147:697–701. doi:10.1001/archdermatol.2011.147.

    Article  PubMed  Google Scholar 

  132. Hotz C, Valeyrie-Allanore L, Haddad C, et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol. 2013;169:1223–32. doi:10.1111/bjd.12502.

    Article  CAS  PubMed  Google Scholar 

  133. Fernando SL. Acute generalised exanthematous pustulosis. Australas J Dermatol. 2012;53:87–92. doi:10.1111/j.1440-0960.2011.00845.x.

    Article  PubMed  Google Scholar 

  134. Krishna S, Ortega-Loayza A, Malakouti N, Brinster N. A rapidly progressive and fatal case of atypical acute generalized exanthematous pustulosis. J Am Acad Dermatol. 2014;71:e89–90. doi:10.1016/j.jaad.2014.03.007.

    Article  PubMed  Google Scholar 

  135. Vigano D’Angelo S, Comp PC, Esmon CT, D’Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest. 1986;77:416–25. doi:10.1172/JCI112319.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61:325–32. doi:10.1016/j.jaad.2008.12.039.

    Article  PubMed  Google Scholar 

  137. McGehee WG, Klotz TA, Epstein DJ, Rapaport SI. Coumarin necrosis associated with hereditary protein C deficiency. Ann Intern Med. 1984;101:59–60.

    Article  CAS  PubMed  Google Scholar 

  138. Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med. 1986;104:659–60.

    Article  CAS  PubMed  Google Scholar 

  139. Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol. 1993;129:766–8.

    Article  CAS  PubMed  Google Scholar 

  140. Eby CS. Warfarin-induced skin necrosis. Hematol Oncol Clin North Am. 1993;7:1291–300.

    CAS  PubMed  Google Scholar 

  141. Chan YC, Valenti D, Mansfield AO, Stansby G. Warfarin induced skin necrosis. Br J Surg. 2000;87:266–72. doi:10.1046/j.1365-2168.2000.01352.x.

    Article  CAS  PubMed  Google Scholar 

  142. Comp PC. Coumarin-induced skin necrosis: incidence, mechanisms, management and avoidance. Drug Saf. 1993;8:128–35. doi:10.2165/00002018-199308020-00003.

    Article  CAS  PubMed  Google Scholar 

  143. Sagi A, Ferder M, Strauch B. Skin necrosis and oral anticoagulant therapy: a review of the literature. Eur J Plast Surg. 1990;. doi:10.1007/BF00177808.

    Google Scholar 

  144. Miura Y, Ardenghy M, Ramasastry S, et al. Coumadin necrosis of the skin: report of four patients. Ann Plast Surg. 1996;37:332–7.

    Article  CAS  PubMed  Google Scholar 

  145. Ellis G, Whitehead MA, Robinson D, et al. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ. 2011;343:d6553–d6553. doi:10.1136/bmj.d6553.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Gelwix TJ, Beeson MS. Warfarin-induced skin necrosis. Am J Emerg Med. 1998;16:541–3. doi:10.1016/S0735-6757(98)90015-8.

    Article  CAS  PubMed  Google Scholar 

  147. Alves DW, Chen IA. Warfarin-induced skin necrosis. Hosp Physician. 2002;38:39–42.

    Google Scholar 

  148. Teepe RGC. Recurrent coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol. 1986;122:1408. doi:10.1001/archderm.1986.01660240072019.

    Article  CAS  PubMed  Google Scholar 

  149. Kaiber FL, Malucelli TO, Baroni E, do RV, et al. Trombocitopenia induzida por heparina e necrose cutânea por varfarina: relato de caso. An Bras Dermatol. 2010;85:915–8. doi:10.1590/S0365-05962010000600024.

    Article  PubMed  Google Scholar 

  150. Taheri A, Abdali H. Warfarin induced massive and bilateral skin necrosis of the breasts: a case report and review of the literatures. Acta Med Iran. 2005;43:303–5.

    Google Scholar 

  151. Canturk E. Warfarin-induced skin necrosis: a “novel” solution to an old problem. Turk Kardiyol Dern Ars. 2014;42:787. doi:10.5543/tkda.2014.82342.

    Article  PubMed  Google Scholar 

  152. Bakoyiannis C, Karaolanis G, Patelis N, et al. Dabigatran in the treatment of warfarin-induced skin necrosis: a new hope. Case Rep Dermatol Med. 2016;2016:1–3. doi:10.1155/2016/3121469.

    Article  Google Scholar 

  153. Carlos-Alves J, Soares I, Cruz J, Ferreira A. Severe skin necrosis induced by warfarin. Eur J Intern Med. 2013;24:e235. doi:10.1016/j.ejim.2013.08.601.

    Article  Google Scholar 

  154. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164:66. doi:10.1001/archinte.164.1.66.

    Article  PubMed  Google Scholar 

  155. Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol. 1999;62:44–8.

    Article  CAS  PubMed  Google Scholar 

  156. White PW, Sadd JR, Nensel RE. Thrombotic complications of heparin therapy: including six cases of heparin-induced skin necrosis. Ann Surg. 1979;190:595–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Tietge Schmidt, Jackel E, Trautwein C. Low molecular weight heparin-induced skin necrosis occurring distant from injection sites and without thrombocytopenia. J Intern Med. 1998;243:313–5. doi:10.1046/j.1365-2796.1998.00304.x.

    Article  CAS  PubMed  Google Scholar 

  158. Sherif K, Tello W, Nugent K. Enoxaparin-associated skin necrosis in an older patient: a rare side effect. Clin Geriatr. 2012;20:44–8.

    Google Scholar 

  159. Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost. 1997;78:785–90.

    CAS  PubMed  Google Scholar 

  160. Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804–12.

    Article  CAS  PubMed  Google Scholar 

  161. Coelho J, Izadi D, Gujral S. Enoxaparin-induced skin necrosis. Eplasty. 2016;16:ic4.

    Google Scholar 

  162. Tonn ME, Schaiff RA, Kollef MH. Enoxaparin-associated dermal necrosis: a consequence of cross-reactivity with heparin-mediated antibodies. Ann Pharmacother. 1997;31:323–6.

    Article  CAS  PubMed  Google Scholar 

  163. Fabris F, Luzzatto G, Soini B, et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med. 2002;252:149–54.

    Article  CAS  PubMed  Google Scholar 

  164. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35:9–16 (discussion 35–6).

    CAS  PubMed  Google Scholar 

  165. Menajovsky LB. Heparin-induced thrombocytopenia: clinical manifestations and management strategies. Am J Med. 2005;118(Suppl. 8A):21S–30S. doi:10.1016/j.amjmed.2005.06.005.

    Article  CAS  PubMed  Google Scholar 

  166. Skelley JW, Kyle JA, Roberts RA. Novel oral anticoagulants for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2016;42:172–8. doi:10.1007/s11239-016-1365-0.

    Article  CAS  PubMed  Google Scholar 

  167. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838–43.

    Article  CAS  PubMed  Google Scholar 

  168. Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol. 1996;8:34–40.

    Article  CAS  PubMed  Google Scholar 

  169. af Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical and laboratory features of 82 patients seen in private practice. Arch Dermatol. 1984;120:484. doi:10.1001/archderm.1984.01650400066014.

    Article  Google Scholar 

  170. Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med. 1997;102:186–91.

    Article  CAS  PubMed  Google Scholar 

  171. Mullick FG, McAllister HA, Wagner BM, Fenoglio JJ. Drug related vasculitis: clinicopathologic correlations in 30 patients. Hum Pathol. 1979;10:313–25.

    Article  CAS  PubMed  Google Scholar 

  172. Michel BA, Hunder GG, Bloch DA, Calabrese LH. Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders. J Rheumatol. 1992;19:721–8.

    CAS  PubMed  Google Scholar 

  173. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337:1512–23. doi:10.1056/NEJM199711203372106.

    Article  CAS  PubMed  Google Scholar 

  174. Sais G, Vidaller A, Jucglà A, et al. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998;134:309. doi:10.1001/archderm.134.3.309.

    Article  CAS  PubMed  Google Scholar 

  175. Gao Y, Zhao M-H. Review article: drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology. 2009;14:33–41. doi:10.1111/j.1440-1797.2009.01100.x.

    Article  CAS  PubMed  Google Scholar 

  176. Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12–7.

    PubMed  Google Scholar 

  177. Kallenberg CGM. Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol. 2014;10:484–93. doi:10.1038/nrrheum.2014.104.

    Article  CAS  PubMed  Google Scholar 

  178. Lai Q-Y, Ma T-T, Li Z-Y, et al. Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients. J Rheumatol. 2014;41:1849–55. doi:10.3899/jrheum.131426.

    Article  PubMed  Google Scholar 

  179. Gallardo M de los A, Scolnik M, Pompermayer L, et al. Elderly versus younger patients with ANCA-associated vasculitis. Arthritis Rheumatol. 2015;67.

  180. Sontheimer RD, Maddison PJ, Reichlin M, et al. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med. 1982;97:664–71.

    Article  CAS  PubMed  Google Scholar 

  181. Lowe GC, Lowe G, Henderson CL, et al. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2011;164:465–72. doi:10.1111/j.1365-2133.2010.10110.x.

    CAS  PubMed  Google Scholar 

  182. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985;103:49–51.

    Article  CAS  PubMed  Google Scholar 

  183. Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol. 2010;146:1113–6. doi:10.1001/archdermatol.2010.258.

    Article  PubMed  Google Scholar 

  184. Zarkavelis G, Kollas A, Kampletsas E, et al. Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: a review. J Adv Res. 2016;7:719–26. doi:10.1016/j.jare.2016.04.001.

    Article  PubMed  PubMed Central  Google Scholar 

  185. Wong NY, Parsons LM, Trotter MJ, Tsang RY. Drug-induced subacute cutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report. BMC Res Notes. 2014;7:785. doi:10.1186/1756-0500-7-785.

    Article  PubMed  PubMed Central  Google Scholar 

  186. Marchetti MA, Noland MM, Dillon PM, Greer KE. Taxane associated subacute cutaneous lupus erythematosus. Dermatol Online J. 2013;19:19259.

    CAS  PubMed  Google Scholar 

  187. Lamond NWD, Younis T, Purdy K, Dorreen MS. Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy. Curr Oncol. 2013;20:484. doi:10.3747/co.20.1546.

    Article  Google Scholar 

  188. Grönhagen CM, Fored CM, Linder M, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167:296–305. doi:10.1111/j.1365-2133.2012.10969.x.

    Article  PubMed  CAS  Google Scholar 

  189. Darken M, McBurney EI. Subacute cutaneous lupus erythematosus-like drug eruption due to combination diuretic hydrochlorothiazide and triamterene. J Am Acad Dermatol. 1988;18:38–42.

    Article  CAS  PubMed  Google Scholar 

  190. Brown CW, Deng JS. Thiazide diuretics induce cutaneous lupus-like adverse reaction. J Toxicol Clin Toxicol. 1995;33:729–33.

    Article  CAS  PubMed  Google Scholar 

  191. Lorentz K, Booken N, Goerdt S, Goebeler M. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. J Dtsch Dermatol. 2008;6(823–7):823–8. doi:10.1111/j.1610-0387.2008.06806.x.

    Google Scholar 

  192. Kasperkiewicz M, Anemüller W, Angelova-Fischer I, et al. Subacute cutaneous lupus erythematosus associated with terbinafine. Clin Exp Dermatol. 2009;34:e403–4. doi:10.1111/j.1365-2230.2009.03380.x.

    Article  CAS  PubMed  Google Scholar 

  193. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13. doi:10.1001/archinternmed.2007.106.

    Article  PubMed  Google Scholar 

  194. Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry. 2000;5:149–53. doi:10.153/SCNP00500149.

  195. Flacker JM, Cummings V, Mach JR, et al. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry. 1998;6:31–41.

    Article  CAS  PubMed  Google Scholar 

  196. Davies P. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;308:1403. doi:10.1016/S0140-6736(76)91936-X.

    Article  Google Scholar 

  197. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401. doi:10.1001/jamainternmed.2014.7663.

    Article  PubMed  PubMed Central  Google Scholar 

  198. Agarwal V, O’Neill PJ, Cotton BA, et al. Prevalence and risk factors for development of delirium in burn intensive care unit patients. J Burn Care Res. 2010;31:706–15. doi:10.1097/BCR.0b013e3181eebee9.

    Article  PubMed  PubMed Central  Google Scholar 

  199. Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2006;33:66–73. doi:10.1007/s00134-006-0399-8.

    Article  PubMed  Google Scholar 

  200. Gaudreau J-D, Gagnon P, Harel F, et al. Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol. 2005;23:6712–8. doi:10.1200/JCO.2005.05.140.

    Article  CAS  PubMed  Google Scholar 

  201. Gaudreau J-D, Gagnon P, Roy M-A, et al. Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer. 2007;09:2365–73. doi:10.1002/cncr.22665.

    Article  CAS  Google Scholar 

  202. Schreiber MP, Colantuoni E, Bienvenu OJ, et al. Corticosteroids and transition to delirium in patients with acute lung injury. Crit Care Med. 2014;42:1480–6. doi:10.1097/CCM.0000000000000247.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  203. Pandharipande PP, Girard TD, Jackson JC, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369:1306–16. doi:10.1056/NEJMoa1301372.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  204. Sgonc R, Gruber J. Age-related aspects of cutaneous wound healing: a mini-review. Gerontology. 2013;59:159–64. doi:10.1159/000342344.

    Article  PubMed  Google Scholar 

  205. Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? JAMA. 2007;297:77. doi:10.1001/jama.297.1.77.

    Article  PubMed  Google Scholar 

  206. Dodiuk-Gad RP, Olteanu C, Feinstein A, et al. Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2016;175:422–4. doi:10.1111/bjd.14799.

    Article  CAS  PubMed  Google Scholar 

  207. Jones C, Griffiths RD, Humphris G, Skirrow PM. Memory, delusions, and the development of acute posttraumatic stress disorder-related symptoms after intensive care. Crit Care Med. 2001;29:573–80.

    Article  CAS  PubMed  Google Scholar 

  208. Jackson JC, Pandharipande PP, Girard TD, et al. Depression, posttraumatic stress disorder, and functional disability in survivors of critical illness: results from the BRAIN ICU (bringing to light the risk factors and incidence of neuropsychological dysfunction in ICU survivors) Investigation: a longitudinal cohort study. Lancet Respir Med. 2014;2:369–79. doi:10.1016/S2213-2600(14)70051-7.

    Article  PubMed  PubMed Central  Google Scholar 

  209. Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc. 2001;49:516–22.

    Article  CAS  PubMed  Google Scholar 

  210. Harari D, Hopper A, Dhesi J, et al. Proactive care of older people undergoing surgery (‘POPS’): designing, embedding, evaluating and funding a comprehensive geriatric assessment service for older elective surgical patients. Age Ageing. 2007;36:190–6. doi:10.1093/ageing/afl163.

    Article  PubMed  Google Scholar 

  211. Partridge JSL, Harari D, Martin FC, Dhesi JK. The impact of pre-operative comprehensive geriatric assessment on postoperative outcomes in older patients undergoing scheduled surgery: a systematic review. Anaesthesia. 2014;69(Suppl. 1):8–16. doi:10.1111/anae.12494.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Toronto, Toronto, ON, Canada

    James W. S. Young & Neil H. Shear

  2. Brampton Civic Hospital, N4.760, 2100 Bovaird Drive East, Brampton, ON, L6R 3J7, Canada

    James W. S. Young

Authors
  1. James W. S. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil H. Shear
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James W. S. Young.

Ethics declarations

Funding

No funding was received for the preparation of this review.

Conflict of interest

James Young and Neil Shear have no conflicts of interest directly relevant to the content of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Young, J.W.S., Shear, N.H. Cutaneous Drug Reactions in the Elderly. Drugs Aging 34, 655–672 (2017). https://doi.org/10.1007/s40266-017-0483-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-017-0483-5

Search

Navigation